Page 179 - 2021_04-Haematologica-web

Efficacy of UVC-treated platelets
Roten Kreuzes) and Macopharma for the development of the UVC-based PI technology for platelets, and honoraria for advi- sory board memberships for Grifols, Quotient and Imusyn. DK, BM, AV, SK, HGD, FS, MW, HS, ES, H-HK, AD and EKP have no conflicts of interest to disclose.
Contributions
AS, GB, THM, PP, VB contributed to the conception and design of the study; GB, VB, DK, BM, AV, JC, UR, SK, NA, RP, HGD, FS, MW, HS, TT, H-H K, AD, EKP contributed to the acquisition of data; AS, THM, PP analyzed and interpreted the data and wrote the manuscript; GB and ES contributed to the interpretation of the data. All authors critically reviewed and revised the manuscript content and checked the final version of the manuscript. All authors are accountable for all aspects of the work.
Acknowledgments
We are very grateful to all patients who agreed to participate in the CAPTURE trial. Most sincere thanks to Jana Reins, Sabrina Pigur and Doreen Chudziak for study monitoring, to the nursing staff at all participating hospitals for their support, and to Andreas Greinacher (chairman DSMB), Hannes Wandt (member DSMB), and Thomas Kohlmann (member DSMB) for
safety oversight. Many thanks to Nancy Heddle for her scientific advice on the design of the study.
Moreover, we wish to thank all blood bank personnel from the German Red Cross Blood Transfusion Service in Frankfurt, Germany and the German Red Cross Blood Service NSTOB in Oldenburg and Springe, Germany for their assistance in the col- lection, processing, quality monitoring and distribution of the platelet products, and give special thanks to Sarah Dombos, Mesut Karatas, Sebastian Haase, Maren Schepers, Katrin Dahse, Hagen Baume, Ute Gravemann and Anke Wenk. Thanks also to Franz Wagner, Irene Mardt, Nicola Gökbuket and Ina Müller for assessing and processing the serious adverse events.
Thanks to all data managers and statisticians from the Alcedis, Contract Research Organization in Gießen, Germany, particu- larly Marina Mangold, Sascha Wurmbach, Philipp Schnecko and Claudia Lorenz-Schlüter, and to Macopharma for technical support.
Funding
This work was supported by the Research Foundation of the German Red Cross Blood Services (Forschungsgemeinschaft der Blutspendedienste des Deutschen Roten Kreuzes) and Macopharma S.A.S. Macopharma had no role in data collection, study management or data analyses.
References
1. Stramer SL. Current perspectives in transfu- sion-transmitted infectious diseases: emerging and re-emerging infections. ISBT Sci Ser. 2014;9(1):30-36.
2. Lanteri MC, Kleinman SH, Glynn SA, et al. Zika virus: a new threat to the safety of the blood supply with worldwide impact and implications. Transfusion. 2016;56(7):1907- 1914.
3. Jutzi M, Mansouri Taleghani B, Rueesch M, Amsler L, Buser A. Nationwide implemen- tation of pathogen inactivation for all platelet concentrates in Switzerland. Transfus Med Hemother. 2018;45(3):151- 156.
4. Godbey EA, Thibodeaux SR. Ensuring safe- ty of the blood supply in the United States: donor screening, testing, emerging pathogens, and pathogen inactivation. Semin Hematol. 2019;56(4):229-235.
5. Seltsam A, Muller TH. Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol. 2013; 162(4):442-454.
6. Seltsam A, Muller TH. UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother. 2011;38(1):43-54.
7. Mohr H, Gravemann U, Bayer A, Muller TH. Sterilization of platelet concentrates at production scale by irradiation with short- wave ultraviolet light. Transfusion. 2009;49(9):1956-1963.
8. Castro E, Gonzalez LM, Rubio JM, Ramiro R, Girones N, Montero E. The efficacy of the ultraviolet C pathogen inactivation sys- tem in the reduction of Babesia divergens in pooled buffy coat platelets. Transfusion. 2014;54(9):2207-2216.
9. Eickmann M, Gravemann U, Handke W, et al. Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultravi- olet C light and methylene blue plus visible light, respectively. Transfusion.
2018;58(9):2202-2207.
10.Faddy HM, Fryk JJ, Prow NA, et al.
1541.
19. Cazenave JP, Folléa G, Bardiaux L, et al. A
randomized controlled clinical trial evaluat- ing the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion. 2010;50(11):2362- 2375.
20. Kerkhoffs JL, van Putten WL, Novotny VM, et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol. 2010;150(11):209-217.
21. Janetzko K, Cazenave JP, Kluter H, et al. Therapeutic efficacy and safety of photo- chemically treated apheresis platelets processed with an optimized integrated set. Transfusion. 2005;45(9):1443-1452.
22. Lozano M, Knutson F, Tardivel R, et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol. 2011;153(3):393-401.
23. Rebulla P, Vaglio S, Beccaria F, et al. Clinical effectiveness of platelets in additive solu- tion treated with two commercial pathogen-reduction technologies. Transfusion. 2017;57(5):1171-1183.
24.Sigle JP, Infanti L, Studt JD, et al. Comparison of transfusion efficacy of amo- tosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components. Transfusion. 2013;53(8):1788- 1797.
25. van der Meer PF, Ypma PF, van Geloven N, et al. Hemostatic efficacy of pathogen-inac- tivated vs untreated platelets: a random- ized controlled trial. Blood. 2018;132(2):223-231.
26. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362(7):600-613.
27. Seigeot A, Desmarets M, Rumpler A, et al. Factors related to the outcome of prophy- lactic platelet transfusions in patients with
11.
Inactivation of dengue, chikungunya, and Ross River viruses in platelet concentrates after treatment with ultraviolet C light. Transfusion. 2016;56(6):1548-1555. Steinmann E, Gravemann U, Friesland M, et al. Two pathogen reduction technolo- gies--methylene blue plus light and short- wave ultraviolet light--effectively inacti- vate hepatitis C virus in blood products. Transfusion. 2013;53(5):1010-1018.
12. Gravemann U, Handke W, Muller TH, Seltsam A. Bacterial inactivation of platelet concentrates with the THERAFLEX UV- Platelets pathogen inactivation system. Transfusion. 2019;59(4):1324-1332.
13.Pohler P, Muller M, Winkler C, et al. Pathogen reduction by ultraviolet C light effectively inactivates human white blood cells in platelet products. Transfusion. 2015;55(2):337-347.
14. Pohler P, Lehmann J, Veneruso V, et al. Evaluation of the tolerability and immuno- genicity of ultraviolet C-irradiated autolo- gous platelets in a dog model. Transfusion. 2012;52(11):2414-2426.
15. Thiele T, Pohler P, Kohlmann T, et al. Tolerance of platelet concentrates treated with UVC-light only for pathogen reduc- tion--a phase I clinical trial. Vox Sang. 2015;109(1):44-51.
16. Bashir S, Cookson P, Wiltshire M, et al. Pathogen inactivation of platelets using ultraviolet C light: effect on in vitro func- tion and recovery and survival of platelets. Transfusion. 2013;53(5):990-1000.
17. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photo- chemical pathogen inactivation treatment: the euroSPRITE trial. Blood. 2003;101(6):2426-2433.
18. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood. 2004;104(5):1534-
haematologica | 2021; 106(4)
1095